Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has been assigned an average rating of “Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Nine research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has received an average rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is […]
Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its target price reduced by Royal Bank of Canada from $53.00 to $50.00 in a research report report published on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock. PLRX has been the subject of a number of other research reports. […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]
Rhenman & Partners Asset Management AB acquired a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 330,635 shares of the company’s stock, valued at approximately $5,733,000. Rhenman & Partners Asset Management AB […]